OA12362A - Substituted imidazoles as tafia inhibitors. - Google Patents
Substituted imidazoles as tafia inhibitors. Download PDFInfo
- Publication number
- OA12362A OA12362A OA1200300039A OA1200300039A OA12362A OA 12362 A OA12362 A OA 12362A OA 1200300039 A OA1200300039 A OA 1200300039A OA 1200300039 A OA1200300039 A OA 1200300039A OA 12362 A OA12362 A OA 12362A
- Authority
- OA
- OAPI
- Prior art keywords
- formula
- compound
- preparation
- hydrogen
- compounds
- Prior art date
Links
- 0 CC1(CCCCCC1)C1(CN(*)CNC1)C(*)=C(*(*)C(*)(*)C(*)(*)N1*)C1=O Chemical compound CC1(CCCCCC1)C1(CN(*)CNC1)C(*)=C(*(*)C(*)(*)C(*)(*)N1*)C1=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0020346A GB0020346D0 (en) | 2000-08-17 | 2000-08-17 | Pharmaceuticals |
GB0027409A GB0027409D0 (en) | 2000-11-09 | 2000-11-09 | Pharmaceuticals |
GB0029556A GB0029556D0 (en) | 2000-12-04 | 2000-12-04 | Pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12362A true OA12362A (en) | 2004-04-07 |
Family
ID=27255849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200300039A OA12362A (en) | 2000-08-17 | 2001-08-08 | Substituted imidazoles as tafia inhibitors. |
Country Status (38)
Country | Link |
---|---|
EP (1) | EP1311488B1 (de) |
JP (2) | JP4119746B2 (de) |
KR (1) | KR20030022412A (de) |
CN (1) | CN1443173A (de) |
AP (1) | AP1375A (de) |
AR (1) | AR035580A1 (de) |
AT (1) | ATE447557T1 (de) |
AU (1) | AU2001276605A1 (de) |
BG (1) | BG107330A (de) |
BR (1) | BR0113289A (de) |
CA (1) | CA2419633C (de) |
CY (1) | CY1109693T1 (de) |
CZ (1) | CZ2003388A3 (de) |
DE (1) | DE60140368D1 (de) |
DK (1) | DK1311488T3 (de) |
DO (1) | DOP2001000233A (de) |
EA (1) | EA005532B1 (de) |
EE (1) | EE200300070A (de) |
ES (1) | ES2334101T3 (de) |
HR (1) | HRP20030103A2 (de) |
HU (1) | HUP0303763A3 (de) |
IL (1) | IL153225A0 (de) |
IS (1) | IS6638A (de) |
MA (1) | MA26940A1 (de) |
MX (1) | MXPA03001425A (de) |
NO (1) | NO20030706L (de) |
NZ (1) | NZ522823A (de) |
OA (1) | OA12362A (de) |
PA (1) | PA8525401A1 (de) |
PE (1) | PE20020352A1 (de) |
PL (1) | PL361054A1 (de) |
PT (1) | PT1311488E (de) |
SI (1) | SI1311488T1 (de) |
SK (1) | SK1732003A3 (de) |
SV (1) | SV2002000602A (de) |
TN (1) | TNSN01126A1 (de) |
UY (1) | UY26889A1 (de) |
WO (1) | WO2002014285A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0103272D0 (sv) | 2001-09-28 | 2001-09-28 | Astrazeneca Ab | Chemical compounds |
OA12756A (en) * | 2002-01-22 | 2006-07-03 | Pfizer | 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors. |
US6713496B2 (en) | 2002-01-22 | 2004-03-30 | Pfizer Inc | 3-(imidazolyl)-2-alkoxypropanoic acids |
CA2472239A1 (en) | 2002-01-22 | 2003-07-31 | Pfizer Inc. | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
DE602004024879D1 (de) | 2003-04-29 | 2010-02-11 | Univ Zuerich | AN EINEM BIOMOLEKÜL GEBUNDENEN N epsilon- UND/ODER N alpha DERIVATISIERTEM UND ORGANISCH-GESCHÜTZTEM L-HISTIDIN ZUR HOCH-EFFIZIENTER MARKIERUNG MIT (M(H2O)3(CO)3)+ MITTELS FAC KOORDINIERUNG |
SE0302853D0 (sv) * | 2003-10-29 | 2003-10-29 | Astrazeneca Ab | Chemical compounds |
US20050137142A1 (en) * | 2003-11-03 | 2005-06-23 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
CA2604912A1 (en) * | 2005-04-18 | 2006-10-26 | Bayer Schering Pharma Aktiengesellschaft | Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
DE102005049385A1 (de) * | 2005-10-15 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Imidazolderivate als Inhibitoren von TAFIa |
PT2104497E (pt) * | 2006-12-06 | 2015-06-09 | Sanofi Sa | Derivados de ureia e sulfamida enquanto inibidores de tafia |
WO2009103432A2 (en) * | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
CA2741783A1 (en) | 2008-10-29 | 2010-05-06 | Taisho Pharmaceutical Co., Ltd. | Compounds having tafia inhibitory activity |
FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
RS56445B1 (sr) * | 2010-03-18 | 2018-01-31 | Daiichi Sankyo Co Ltd | Cikloalkil-supstituisani imidazolni derivat |
KR20130006620A (ko) | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | 시클로프로판카르복실산 유도체 |
AP3694A (en) * | 2011-05-17 | 2016-04-30 | Joint Stock Company "Pharmasyntez" | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process |
CN103748077B (zh) * | 2011-07-22 | 2016-08-17 | 坎布雷卡尔斯库加公司 | 用于制备4-取代咪唑类的方法 |
WO2013039202A1 (ja) * | 2011-09-15 | 2013-03-21 | 第一三共株式会社 | 新規アクリル酸誘導体 |
MX2015016961A (es) | 2013-06-10 | 2016-04-25 | Sanofi Sa | Derivados de urea macrociclicos como inhibidores de tafia, su preparacion y su uso como productos farmaceuticos. |
ES2949852T3 (es) | 2015-10-07 | 2023-10-03 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
KR20180123038A (ko) | 2016-03-29 | 2018-11-14 | 다이이찌 산쿄 가부시키가이샤 | 염증성 장질환 치료제 |
EP3442948B1 (de) * | 2016-04-13 | 2020-12-16 | Mitobridge, Inc. | Ppar-agonisten, verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung davon |
CN113943255B (zh) * | 2020-07-17 | 2024-08-06 | 深圳信立泰药业股份有限公司 | 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6163661A (ja) * | 1984-09-05 | 1986-04-01 | Microbial Chem Res Found | ヒスタジン関連化合物 |
US5993815A (en) * | 1996-11-08 | 1999-11-30 | University Of Vermont | Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI) |
SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
-
2001
- 2001-08-08 PL PL36105401A patent/PL361054A1/xx not_active Application Discontinuation
- 2001-08-08 CZ CZ2003388A patent/CZ2003388A3/cs unknown
- 2001-08-08 DE DE60140368T patent/DE60140368D1/de not_active Expired - Lifetime
- 2001-08-08 DK DK01954264T patent/DK1311488T3/da active
- 2001-08-08 CA CA2419633A patent/CA2419633C/en not_active Expired - Fee Related
- 2001-08-08 PT PT01954264T patent/PT1311488E/pt unknown
- 2001-08-08 HU HU0303763A patent/HUP0303763A3/hu unknown
- 2001-08-08 MX MXPA03001425A patent/MXPA03001425A/es active IP Right Grant
- 2001-08-08 WO PCT/IB2001/001425 patent/WO2002014285A1/en not_active Application Discontinuation
- 2001-08-08 AU AU2001276605A patent/AU2001276605A1/en not_active Abandoned
- 2001-08-08 SK SK173-2003A patent/SK1732003A3/sk unknown
- 2001-08-08 KR KR10-2003-7002279A patent/KR20030022412A/ko not_active Application Discontinuation
- 2001-08-08 NZ NZ522823A patent/NZ522823A/en unknown
- 2001-08-08 IL IL15322501A patent/IL153225A0/xx unknown
- 2001-08-08 ES ES01954264T patent/ES2334101T3/es not_active Expired - Lifetime
- 2001-08-08 AT AT01954264T patent/ATE447557T1/de active
- 2001-08-08 OA OA1200300039A patent/OA12362A/fr unknown
- 2001-08-08 SI SI200130950T patent/SI1311488T1/sl unknown
- 2001-08-08 JP JP2002519428A patent/JP4119746B2/ja not_active Expired - Fee Related
- 2001-08-08 EA EA200201239A patent/EA005532B1/ru not_active IP Right Cessation
- 2001-08-08 CN CN01813131A patent/CN1443173A/zh active Pending
- 2001-08-08 EE EEP200300070A patent/EE200300070A/xx unknown
- 2001-08-08 BR BR0113289-0A patent/BR0113289A/pt not_active Application Discontinuation
- 2001-08-08 EP EP01954264A patent/EP1311488B1/de not_active Expired - Lifetime
- 2001-08-14 PA PA20018525401A patent/PA8525401A1/es unknown
- 2001-08-15 PE PE2001000815A patent/PE20020352A1/es not_active Application Discontinuation
- 2001-08-15 AR ARP010103900A patent/AR035580A1/es unknown
- 2001-08-15 UY UY26889A patent/UY26889A1/es not_active Application Discontinuation
- 2001-08-16 TN TNTNSN01126A patent/TNSN01126A1/fr unknown
- 2001-08-16 SV SV2001000602A patent/SV2002000602A/es unknown
- 2001-08-16 AP APAP/P/2001/002250A patent/AP1375A/en active
- 2001-11-14 DO DO2001000233A patent/DOP2001000233A/es unknown
-
2002
- 2002-11-28 IS IS6638A patent/IS6638A/is unknown
- 2002-11-28 BG BG107330A patent/BG107330A/xx unknown
-
2003
- 2003-02-04 MA MA27025A patent/MA26940A1/fr unknown
- 2003-02-13 HR HR20030103A patent/HRP20030103A2/hr not_active Application Discontinuation
- 2003-02-14 NO NO20030706A patent/NO20030706L/no not_active Application Discontinuation
-
2008
- 2008-02-27 JP JP2008045382A patent/JP4778531B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-30 CY CY20091101349T patent/CY1109693T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA12362A (en) | Substituted imidazoles as tafia inhibitors. | |
US10308632B2 (en) | Antifungal compounds and processes for making | |
CZ20003890A3 (cs) | Substituovaný benzamid, způsob jeho přípravy a jeho pouľití jako inhibitoru cysteinproteasy | |
CZ287610B6 (cs) | Pentanamidové deriváty a farmaceutický prostředek s jejich obsahem | |
TW201240975A (en) | Metalloenzyme inhibitor compounds | |
US6759426B2 (en) | 3-(Imidazolyl)-2-aminopropanoic acids | |
EA002971B1 (ru) | Ингибиторы металлопротеаз матрикса, способы их получения, фармкомпозиция, применение и способ лечения | |
HRP20040659A2 (en) | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors | |
US6713496B2 (en) | 3-(imidazolyl)-2-alkoxypropanoic acids | |
US6949577B2 (en) | Pharmaceuticals | |
JP3588363B2 (ja) | キノキサリンジオン類 | |
JPH05504146A (ja) | シクロアルキル置換グルタルアミド降圧剤 | |
US20020147229A1 (en) | Pharmaceuticals | |
TWI692476B (zh) | 環丁基-咪唑啶酮化合物 | |
JPH10510534A (ja) | 2−(2,3,5,6−テトラフルオロ−4−ピリジル)−1,2,5−チアジアゾリジン−3−オン=1,1−ジオキシド並びにその組成物及び使用方法 | |
ZA200301230B (en) | Substituted imidazoles as tafia inhibitors. | |
AU2003237012A1 (en) | 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors | |
JPS63270649A (ja) | 5−置換アミノ−4−ヒドロキシペンテン酸誘導体及びその用途 | |
JPH02196723A (ja) | リン含有酵素阻害剤 |